Navigation Links
AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin,Cells Have the Ability to Recognize, Transport and Utilize,L-ergothioneine (EGT) As A Protector Against Oxidative Damage

Clinical Poster Presented at Society for Investigative Dermatology

FREEPORT, N.Y., May 16, 2007 /PRNewswire/ -- AGI Dermatics recently announced new comparative clinical data that indicates that OCTN-1 skin cells have the ability to recognize, transport and utilize L-ergothioneine (EGT) as a protector against oxidative damage, and importantly, that (EGT) acts as a more powerful and efficient antioxidant than idebenone, scavenging reactive oxygen species and reducing UV-induced hydrogen peroxide (H2O2). The data was presented at the 68th Annual Meeting of the Society for Investigative Dermatology, May 9 - 12, in Los Angeles, CA.

"We are very excited that this clinical work demonstrates that OCTN-1 plays a vital role in the active accumulation and utilization of EGT for the treatment of photodamaged skin," said Daniel Yarosh, PhD, President, AGI Dermatics. "This data confirms that L-ergothioneine is a natural part of the skin's antioxidant system."

EGT is an exclusive and maximized natural amino acid that has been used in topical applications. The cellular receptor and transporter for EGT, OCTN-1 has recently been identified and is responsible for the intracellular accumulation of this naturally occurring antioxidant. However, there have been questions of the role of EGT and its receptor/transport, OCTN-1.

To examine this, the mRNA expression in cultured normal human epidermal keratinocytes (NHEK) and normal human dermal fibroblasts (NHDF) was analyzed. Results indicate OCTN-1 mRNA was detectable equally in both NHEK and NHDF with quantitative measurements by real-time PCR. To further investigate any differences in production of OCTN-1 and to assure production of OCTN-1 in both NHEK and NHDF, the study also looked at the transcription of the OCTN-1 mRNA into OCTN-1 protein. Results indicate OCTN-1 protein isoforms were more abundant in NHDF than NHEK, though still detectable in NHEK, as shown by western, blot analysis.

The study also examined whether this new patented form of EGT further exhibited properties of a super-antioxidant, and therefore EGT's beneficial role in the treatment of photodamaged skin. Study results show that NHDF treated with EGT had significant lower levels of hydroxyl radicals over a one-hour period than those treated with idebenone, a synthesized form of CoQ10 which has also been thought to exhibit exceptional antioxidant properties.

AGI Dermatics is the developer of Remergent(R), a doctor-dispensed skincare line based on the science of DNA repair. AGI manufactures Remergent(R) Clarifying Concentrate, a formula designed to treat hyperpigmentation, which contains EGT as a key ingredient. EGT has also been shown to be clinically effective in enhancing skin brightness.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. www.agiderm.com

CONTACT: Courtney McGeever for AGI Dermatics, +1-212-317-1462

Web site: http://www.agiderm.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016  RxWiki Inc., a digital ... digital marketing strategies of thousands of pharmacies through its ... Austin Inno,s "50 on Fire" Award in ... "We,re pleased to accept the award as one of ... Chief Executive Officer at RxWiki. "Our platform gives independent ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
(Date:12/8/2016)... , Dec. 8, 2016 Global Interventional ... on the global interventional radiology market analyzes the ... report comprises an elaborate executive summary, including a ... segments and sub-segments. The research is a ... formed the bulk of our research efforts along ...
Breaking Medicine Technology:
(Date:12/9/2016)... - Cincinnati, Ohio (PRWEB) , ... December 09, ... ... the production of miniature, folded, pharmaceutical inserts and outserts. As a means ... Device. This addition will enable Flottman to individually code professional inserts (PIs) ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted to fulfill ... of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It ... could be set up in a matter of minutes, or even seconds. The SAFETY ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions ... Eric Hoessel to vice president of sales. , Litsinger joined Mirixa in ...
Breaking Medicine News(10 mins):